The Bonus Pick
Eli Lilly (LLY) is the bonus name in Porter Stansberry’s Ignition Point pitch, the extra report dangled alongside the four core biotech picks, and it carries the promo’s boldest label: “The NVIDIA of Medicine.” Porter Stansberry, the founder of Porter & Co. and the name behind the long-running Stansberry newsletter family, has a taste for sweeping comparisons, and this one lands on a company that really is extraordinary. Lilly trades around $1,150.99 with a market cap near $1.04 trillion, making it one of the most valuable healthcare companies ever.
The question is not whether Lilly is a great company. It clearly is. The question is whether the NVIDIA comparison holds up against the actual numbers, and that is where the label starts to wobble.
The Comparison That Does Not Hold
The NVIDIA analogy is doing specific work. It borrows the halo of the AI boom’s biggest winner and drapes it over a drug company, implying Lilly is about to deliver the same kind of market-rattling, compounded growth. But the two businesses are growing at wildly different speeds.
NVIDIA’s rich multiple over the AI boom was backed by triple-digit revenue growth, year after year. Lilly, by contrast, is growing at roughly 20 percent. Twenty percent growth is excellent for a company of Lilly’s size, and it is more than enough to justify a premium valuation. What it is not is NVIDIA-style growth, and that matters because the comparison invites investors to expect a trajectory the numbers do not support.
The two companies also sit in different businesses. NVIDIA’s boom was a sudden step change in demand for a single product category, while Lilly’s growth is the steadier grind of a pharmaceutical pipeline rolling out drug after drug over many years. Both can be great investments, but they reward shareholders on very different timelines.
What Lilly Actually Has
None of this should undersell what Lilly has built. The centerpiece of the recent story is Foundayo, the oral weight-loss pill known chemically as orforglipron, which won approval in April 2026. An oral option matters because the blockbuster injectable weight-loss drugs require a weekly needle, and a pill broadens the market to people who will not inject. That is a real catalyst, and it is why Lilly’s forward multiple sits near 30 times earnings.
The injectable versions of these medicines built the category, and their weekly dosing created a convenience gap that an oral pill can close. Foundayo’s approval makes Lilly the first major player with an oral option at scale, a meaningful competitive edge even against rivals with deep obesity franchises.
Lilly is also a diversified pharmaceutical giant with franchises across diabetes, obesity, and oncology, and it is a quiet but real player in the same Lp(a) race the broader promo is built around, through its Dicerna acquisition. That background is covered in our Dicerna breakdown.
The Valuation Math
The simplest way to test the NVIDIA comparison is to put the two numbers the promo gives you side by side. Lilly trades near 30 times forward earnings while growing around 20 percent a year. Divide the multiple by the growth rate and you get a price-to-earnings-to-growth ratio of roughly 1.5, reasonable for a high-quality compounder but not cheap.
Now recall what the NVIDIA analogy implies. NVIDIA earned its towering valuation during the AI boom because revenue was growing at triple-digit rates, which made even a huge multiple look modest once you divided it by growth. Lilly is not growing at triple-digit rates. It is growing at 20 percent, excellent for a $1 trillion company but an order of magnitude short of the comparison the label invites.
None of that makes Lilly a bad investment. A PEG around 1.5 for a dominant pharmaceutical franchise is a defensible price to pay. The point is narrower: the NVIDIA label is a growth analogy, and the growth is not there. Lilly is a quality compounder wearing a disruptor’s costume, and investors should price it as the former rather than hope for the latter.
The Read
The honest read is that Lilly is a superb company with a stretched nickname. Paying roughly 30 times forward earnings for 20 percent growth is defensible, but it is not cheap, and the NVIDIA framing invites a comparison that flatters the marketing more than the math.
The distinction that actually matters is the one the promo blurs: Lilly is a compounding quality business, not a hyper-growth disruptor. That is a fine thing to own, and it is a sensible name to pair with the more speculative picks in a barbell. But investors who buy it expecting NVIDIA’s chart are buying the analogy, not the company. For the broader framework around how these names fit together, see our best biotech stocks guide.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.